Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251737 | 0.89 | DHODH (0.75) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4025228 | 0.85 | DHODH (1.00) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4022761 | 0.85 | DHODH (1.00) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL30338397 | 0.85 | DHODH (1.00) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4025898 | 0.85 | DHODH (1.00) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4022707 | 0.82 | DHODH (0.72) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4022091 | 0.82 | DHODH (0.69) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4022138 | 0.82 | DHODH (0.75) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4021884 | 0.82 | DHODH (0.69) | DHODHALOX15SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4026687 | 0.82 | DHODH (0.69) | DHODHALOX15SMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | claimed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | DHODH 103/4885ALOX15 1407/4885SMN1; SMN2 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.